As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
31 Analysts have issued a Novo Nordisk forecast:
31 Analysts have issued a Novo Nordisk forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 315,603 315,603 |
17%
17%
|
|
| Gross Profit | 258,939 258,939 |
13%
13%
|
|
| EBITDA | 154,277 154,277 |
14%
14%
|
|
| EBIT (Operating Income) EBIT | 132,659 132,659 |
12%
12%
|
|
| Net Profit | 103,773 103,773 |
10%
10%
|
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
| Head office | Denmark |
| CEO | Lars Jørgensen |
| Employees | 76,826 |
| Founded | 1931 |
| Website | www.novonordisk.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


